| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Desvenlafaxine (WY-45233; WY45233; brand names Pristiq, Desfax), the active metabolite of the antidepressant venlafaxine, is a potent inhibitor/antagonist of the reuptake of serotonin (5-HT) transporter and norepinephrine (NE) transporter with Ki of 40.2 nM and 558.4 nM respectively.
| Targets |
hSERT ( IC50 = 47.3 nM ); hNET ( IC50 = 531.3 nM )
|
||
|---|---|---|---|
| ln Vitro |
|
||
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C16H25NO2
|
|
|---|---|---|
| Molecular Weight |
263.38
|
|
| Exact Mass |
263.19
|
|
| Elemental Analysis |
C, 72.96; H, 9.57; N, 5.32; O, 12.15
|
|
| CAS # |
93413-62-8
|
|
| Related CAS # |
Desvenlafaxine succinate hydrate; 386750-22-7; (S)-(+)-O-Desmethyl Venlafaxine-d6; 1062609-99-7; Desvenlafaxine succinate; 448904-47-0; Desvenlafaxine fumarate; 93414-04-1; Desvenlafaxine hydrochloride; 300827-87-6; (S)-(+)-O-Desmethyl Venlafaxine; 142761-12-4; (R)-(-)-O-Desmethyl Venlafaxine-d6; 1062609-96-4; 1147940-37-1 (benzoate)
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O
|
|
| InChi Key |
KYYIDSXMWOZKMP-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3
|
|
| Chemical Name |
4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.49 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.49 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.49 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 0.5% methylcellulose+0.2% Tween 80 : 30 mg/mL |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7968 mL | 18.9840 mL | 37.9680 mL | |
| 5 mM | 0.7594 mL | 3.7968 mL | 7.5936 mL | |
| 10 mM | 0.3797 mL | 1.8984 mL | 3.7968 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00211094 | Completed | Drug: Dapoxetine | Ejaculation | Alza Corporation, DE, USA | June 2004 | Phase 3 |
| NCT01419470 | Completed | Drug: dapoxetine | Premature Ejaculation | Yuhan Corporation | February 2011 | Phase 1 Phase 2 |
| NCT01366664 | Completed | Drug: Treatment sequence 2 Drug: Treatment sequence 1 |
Ejaculation | Janssen Research & Development, LLC |
April 2011 | Phase 1 |
| NCT01063855 | Completed | Drug: Dapoxetine Drug: Placebo |
Erectile Dysfunction Sexual Dysfunction |
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
April 2010 | Phase 3 |
| NCT01230762 | Completed | Drug: dapoxetine | Ejaculation | Alza Corporation, DE, USA | April 2005 | Phase 3 |
|
|---|
|
  |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
